| __timestamp | ACADIA Pharmaceuticals Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 179279000 |
| Thursday, January 1, 2015 | 76369000 | 186359000 |
| Friday, January 1, 2016 | 4406000 | 171785000 |
| Sunday, January 1, 2017 | 13060000 | 208136000 |
| Monday, January 1, 2018 | 18330000 | 198405000 |
| Tuesday, January 1, 2019 | 19598000 | 224169000 |
| Wednesday, January 1, 2020 | 20550000 | 245044000 |
| Friday, January 1, 2021 | 19141000 | 252314000 |
| Saturday, January 1, 2022 | 10166000 | 268225000 |
| Sunday, January 1, 2023 | 45731000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Over this period, Taro consistently reported higher costs, peaking at approximately $324 million in 2024, reflecting a 45% increase from 2014. In contrast, ACADIA's costs fluctuated, with a notable spike in 2023, reaching around $46 million, a significant rise from previous years. This disparity highlights Taro's expansive operations compared to ACADIA's more variable cost structure. Missing data for ACADIA in 2024 suggests potential reporting delays or strategic shifts. These insights underscore the importance of cost management in maintaining competitive advantage and profitability in the pharmaceutical sector.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and Taro Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and ACADIA Pharmaceuticals Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Catalent, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down ADMA Biologics, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Xencor, Inc.
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE